Morgan Stanley
AVXL icon

Morgan Stanley’s Anavex Life Sciences AVXL Stock Holding History

Morgan Stanley’s Portfolio AVXL Stock Details AVXL Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$505K Sell
194,963
-162,784
-46% -$482K ﹤0.01% 5550
2026
Q1 		$1.1M Sell
357,747
-117,109
-25% -$507K ﹤0.01% 5094
2025
Q4 		$1.69M Sell
474,856
-85,292
-15% -$523K ﹤0.01% 4920
2025
Q3 		$4.99M Sell
560,148
-67,059
-11% -$680K ﹤0.01% 4152
2025
Q2 		$5.78M Sell
627,207
-237,521
-27% -$2.03M ﹤0.01% 3941
2025
Q1 		$7.42M Sell
864,728
-39,431
-4% -$372K ﹤0.01% 3595
2024
Q4 		$9.71M Buy
904,159
+185,604
+26% +$1.43M ﹤0.01% 3441
2024
Q3 		$4.08M Buy
718,555
+280,715
+64% +$1.62M ﹤0.01% 4120
2024
Q2 		$1.85M Buy
437,840
+97,210
+29% +$393K ﹤0.01% 4619
2024
Q1 		$1.73M Sell
340,630
-111,573
-25% -$628K ﹤0.01% 4675
2023
Q4 		$4.21M Buy
452,203
+179,960
+66% +$1.24M ﹤0.01% 4050
2023
Q3 		$1.78M Sell
272,243
-171
-0.1% -$1.36K ﹤0.01% 4457
2023
Q2 		$2.21M Buy
272,414
+10,928
+4% +$93.6K ﹤0.01% 4366
2023
Q1 		$2.24M Sell
261,486
-121,997
-32% -$1.22M ﹤0.01% 4387
2022
Q4 		$3.55M Buy
383,483
+165,312
+76% +$1.77M ﹤0.01% 4036
2022
Q3 		$2.25M Sell
218,171
-626,644
-74% -$6.61M ﹤0.01% 4344
2022
Q2 		$8.46M Buy
844,815
+99,208
+13% +$940K ﹤0.01% 3241
2022
Q1 		$9.18M Buy
745,607
+388,392
+109% +$4.78M ﹤0.01% 2999
2021
Q4 		$6.2M Buy
357,215
+107,828
+43% +$2.05M ﹤0.01% 3490
2021
Q3 		$4.48M Sell
249,387
-22,286
-8% -$444K ﹤0.01% 3846
2021
Q2 		$6.21M Buy
271,673
+186,329
+218% +$2.76M ﹤0.01% 3554
2021
Q1 		$1.28M Buy
85,344
+1,926
+2% +$21K ﹤0.01% 4574
2020
Q4 		$450K Buy
83,418
+59,345
+247% +$313K ﹤0.01% 5148
2020
Q3 		$109K Sell
24,073
-17,638
-42% -$75.9K ﹤0.01% 5388
2020
Q2 		$205K Buy
41,711
+12,899
+45% +$48.7K ﹤0.01% 5064
2020
Q1 		$91K Sell
28,812
-60,323
-68% -$210K ﹤0.01% 5221
2019
Q4 		$231K Buy
89,135
+45,870
+106% +$120K ﹤0.01% 5358
2019
Q3 		$137K Buy
43,265
+35,891
+487% +$104K ﹤0.01% 5321
2019
Q2 		$25K Sell
7,374
-12,164
-62% -$37.8K ﹤0.01% 5853
2019
Q1 		$59K Buy
19,538
+11,931
+157% +$28.5K ﹤0.01% 5594
2018
Q4 		$12K Sell
7,607
-3,505
-32% -$7.96K ﹤0.01% 6128
2018
Q3 		$30K Sell
11,112
-84,328
-88% -$238K ﹤0.01% 6024
2018
Q2 		$251K Buy
95,440
+1,327
+1% +$3.71K ﹤0.01% 5455
2018
Q1 		$260K Sell
94,113
-7,101
-7% -$20.1K ﹤0.01% 5356
2017
Q4 		$326K Buy
101,214
+41,289
+69% +$162K ﹤0.01% 5207
2017
Q3 		$247K Buy
59,925
+4,640
+8% +$20.6K ﹤0.01% 5246
2017
Q2 		$294K Buy
55,285
+8,494
+18% +$49.1K ﹤0.01% 5119
2017
Q1 		$268K Sell
46,791
-87,855
-65% -$454K ﹤0.01% 5176
2016
Q4 		$532K Buy
134,646
+125,178
+1,322% +$446K ﹤0.01% 4897
2016
Q3 		$34K Buy
9,468
+3,643
+63% +$15.3K ﹤0.01% 5739
2016
Q2 		$36K Sell
5,825
-23,690
-80% -$114K ﹤0.01% 5640
2016
Q1 		$145K Sell
29,515
-103,081
-78% -$453K ﹤0.01% 5150
2015
Q4 		$738K Buy
+132,596
New +$943K ﹤0.01% 4268

Other funds holding AVXL

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Two Sigma Investments
Two Sigma Investments New York $138B AUM 41.87% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Federated Hermes
Federated Hermes Pittsburgh, Pennsylvania $69.6B AUM 42.52% 1-Year Est. Return
AQR Capital Management
AQR Capital Management Greenwich, Connecticut $287B AUM 42.33% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
SF
Summit Financial Parsippany, New Jersey $9.12B AUM 27.44% 1-Year Est. Return
Goldman Sachs
Goldman Sachs New York $1.15T AUM 47.82% 1-Year Est. Return

Morgan Stanley's AVXL Position: Q2 2026 in Review

Morgan Stanley reduced its Anavex Life Sciences (AVXL) stake by 46% in Q2 2026, selling an estimated $482K and leaving 194,963 shares worth $505K. The position accounts for ﹤0.01% of the portfolio, ranked #5550.

Morgan Stanley first reported a position in AVXL in Q4 2015 and has held it in 43 quarters since. The position peaked at $9.71M in Q4 2024. 179 funds tracked by Wall St. Rank hold AVXL as of Q2 2026.

  • Morgan Stanley held 194,963 shares of Anavex Life Sciences worth $505K as of Q2 2026.
  • Morgan Stanley sold 162,784 Anavex Life Sciences shares in Q2 2026, an estimated $482K.
  • Anavex Life Sciences made up ﹤0.01% of Morgan Stanley's portfolio in Q2 2026, its #5550 holding.
  • Morgan Stanley first reported a position in Anavex Life Sciences in Q4 2015 and has held it in 43 quarters since.
  • Morgan Stanley's Anavex Life Sciences position peaked at $9.71M in Q4 2024.
  • 179 funds tracked by Wall St. Rank held Anavex Life Sciences as of Q2 2026.

Based on Morgan Stanley's 13F filing for Q2 2026, filed 13 Aug 2026.